Peptides vs. Proteins: Structure, Synthesis, and Laboratory Handling

Peptides and proteins are both chains of amino acids connected by peptide bonds, and at the molecular level there is no sharp discontinuity between them. The distinction that matters practically is length. Chains up to approximately 50 amino acid residues are conventionally called peptides; above that range, the term protein is standard. Some literature uses the intermediate term polypeptide for mid-range chains, though usage is inconsistent.

The reason length matters is what it enables structurally. Short peptides typically do not have sufficient chain length to adopt stable secondary structures - alpha helices and beta sheets - in solution. They exist largely as flexible, dynamically averaging structures rather than rigid folded entities. Proteins are long enough for extensive intramolecular hydrogen bonding, hydrophobic packing, and in some cases disulfide bridges to produce a defined three-dimensional shape that persists in solution.

In the context of laboratory research materials, the boundary is meaningful for practical reasons beyond nomenclature. A peptide below 50 residues can be synthesised chemically, confirmed by mass spectrometry to a defined molecular weight, and supplied as lyophilised powder with a relatively straightforward stability profile. A protein typically requires recombinant expression, presents challenges for whole-molecule chemical characterisation, and has stability that is sensitive to conditions affecting its folded state.

Secondary structure refers to local regular arrangements of the backbone - most commonly the alpha helix and the beta sheet - stabilised by hydrogen bonds between backbone amide and carbonyl groups. Tertiary structure is the overall three-dimensional fold of the polypeptide chain, stabilised by a combination of hydrophobic burial, hydrogen bonds, electrostatic interactions, and, in some proteins, disulfide bridges.

Protein biological activity typically depends on tertiary structure. An enzyme active site, a receptor binding domain, or an antibody paratope requires the correct three-dimensional arrangement of residues to function. Conditions that disrupt the fold - elevated temperature, pH outside a narrow range, mechanical shear, or freeze-thaw cycling without appropriate cryoprotection - can denature the protein, abolishing activity while the covalent sequence remains intact. This sensitivity is why protein biologics require careful handling protocols that go well beyond the storage requirements applicable to smaller synthetic peptides.

Short peptides do not have defined tertiary structures in solution under typical laboratory conditions. Some shorter sequences can adopt transient or context-dependent secondary structure - a helical turn, a beta-turn - but these are not the persistent global folds that characterise proteins. This structural difference means that conditions which would denature a protein have much less effect on the chemical integrity of a short synthetic peptide.

Research peptides are produced almost universally by solid-phase chemical synthesis. This approach builds the chain residue by residue under chemical control, yielding material with a defined sequence confirmed by mass spectrometry. The impurity profile - truncated sequences, deletion products - is characteristic of the chemistry used and is characterised per batch by HPLC. The method is well suited to chains below approximately 50 residues; longer chains become progressively more difficult to synthesise at acceptable yield and purity by this route.

Proteins, particularly those longer than 100 residues or with complex disulfide bond patterns, are typically produced by recombinant expression. A DNA sequence encoding the protein is introduced into a host organism - commonly bacteria, yeast, or mammalian cell lines - which transcribes and translates it into protein using its own cellular machinery. Post-translational modifications such as glycosylation, phosphorylation, or signal-peptide cleavage occur in the host and contribute to the final molecule's properties. The impurity profile of recombinant material reflects the biology of the host system rather than synthetic chemistry.

The production route has direct implications for characterisation and documentation. A synthetic peptide can be characterised relatively completely by mass spectrometry and HPLC because the molecule is small and chemically defined. A recombinant protein requires a broader panel of assays - molecular weight confirmation, structural integrity testing, activity measurements, and host-cell protein clearance data - because the biological production process introduces additional sources of variability. The documentation required for a research-grade recombinant protein is accordingly more extensive than for a synthetic peptide.

Electrospray ionisation mass spectrometry is the primary identity confirmation method for synthetic peptides. The mass of the intact molecule confirms that the correct sequence was assembled, because a correct or incorrect synthesis produces a characteristic mass difference. Reverse-phase HPLC provides purity data, separating the target sequence from synthesis-related impurities and reporting the area percentage of the main peak. Together, these two measurements form the core analytical record for a research peptide lot.

Proteins require additional methods. SDS-PAGE provides a molecular weight estimate under denaturing conditions and can identify major truncation or aggregation products. Size-exclusion chromatography characterises the aggregation state and the proportion of material in the expected monomeric or multimeric form. Activity assays are required where the protein's biological activity is part of what is being characterised - binding affinity, enzymatic turnover, or receptor engagement. Each dimension adds characterisation information that is not relevant for short synthetic peptides but is essential for proteins.

The difference in analytical scope means that comparing documentation between peptides and proteins is not straightforward. A certificate of analysis for a synthetic peptide lists mass confirmation and HPLC purity. A characterisation report for a research-grade protein will be longer and more complex. Institutions should evaluate each document type against the applicable standard for that class of material, not against a single universal expectation.

Synthetic peptides in lyophilised form are generally stable over long periods when stored under supplier-specified conditions - typically low temperature and protected from light and moisture for sealed material. The dry powder form eliminates the main aqueous degradation pathways and, unlike proteins, a short synthetic peptide does not have a three-dimensional structure that can be disrupted by storage conditions.

Proteins are sensitive to conditions that affect their folded state. Freeze-thaw cycling can cause aggregation, particularly for proteins at higher concentrations or without cryoprotection. Temperature excursions above the protein's stability range accelerate denaturation. Some proteins require continuous cold-chain management and are unsuited to room-temperature storage at any point during the supply chain. These requirements add complexity and cost to protein shipment and storage that are not generally applicable to lyophilised synthetic peptides.

For laboratories that handle both classes of material, clear separation of storage requirements and documentation practices is important. Applying protein biologic handling standards to small synthetic peptides adds unnecessary operational burden; conversely, handling a sensitive recombinant protein like a synthetic peptide risks material loss through degradation. Suppliers of each class should provide material-specific storage guidance on the certificate of analysis, and laboratory SOPs should reference those compound-specific requirements rather than generic defaults.